Physician profile
Ann Mccarthy
NPI 1598202046
$3,022.59
in general payments reported to CMS, 2019-2025
32 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $295 · 2022: $328 · 2023: $476 · 2024: $903 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.04 | 2021-2025 | |
| Novo Nordisk INC | $327.14 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $258.42 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $201.98 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.57 | 2021-2025 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.95 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $194.91 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $119.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $101.86 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $89.53 | 2022-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Dexcom, INC. | $82.73 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $67.59 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $65.45 | 2023-2025 | |
| Abbott Laboratories | $58.95 | 2021-2025 | Freestyle Libre 2, Thoratec Heartmate 3 Lvas Implant Kit |
| Xeris Pharmaceuticals, INC. | $58.50 | 2023-2024 | Gvoke Hypopen |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.40 | 2022-2025 | Eohilia, Entyvio |
| Esperion Therapeutics, INC. | $50.37 | 2024-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $44.98 | 2021-2022 | |
| Pulmonx Corporation | $43.77 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Edwards Lifesciences Corporation | $42.70 | 2025 | Sapien 3 Ultra Resilia |
| Daiichi Sankyo INC. | $33.93 | 2024-2025 | Injectafer |
| Eisai INC. | $27.98 | 2025 | |
| Amgen INC. | $27.98 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $26.86 | 2023 | Hetlioz |
| Inspire Medical Systems, INC. | $20.89 | 2025 | Inspire |
| Corcept Therapeutics | $20.79 | 2025 | Korlym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.66 | 2025 | Rexulti |
| Agile Therapeutics, INC. | $14.60 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $13.72 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.53 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.